Positive Phase I results for KMO inhibitor in inflammatory disorders
Drug Discovery World
APRIL 22, 2024
Kynos Therapeutics Founder and CSO Damian Mole said: “The headline data from this Phase I study have demonstrated KNS366 is safe and well tolerated at exposures that resulted in a high level of KMO enzyme inhibition.
Let's personalize your content